Simvastatin treatment of hypercholesterolemic mice and monkeys reduced oxLDL, monocyte tissue factor expression, microparticle tissue factor activity, coagulation activation, and inflammation.
Does simvastatin reduce monocyte tissue factor expression and activation of coagulation in hypercholesterolemic models?
Simvastatin reduces the prothrombotic state in hypercholesterolemia by inhibiting oxLDL-mediated induction of tissue factor expression in monocytes.
Hypercholesterolemia is a major risk factor for atherosclerosis. It also is associated with platelet hyperactivity, which increases morbidity and mortality from cardiovascular disease. However, the mechanisms by which hypercholesterolemia produces a procoagulant state remain undefined. Atherosclerosis is associated with accumulation of oxidized lipoproteins within atherosclerotic lesions. Small quantities of oxidized lipoproteins are also present in the circulation of patients with coronary artery disease. We therefore hypothesized that hypercholesterolemia leads to elevated levels of oxidized LDL (oxLDL) in plasma and that this induces expression of the procoagulant protein tissue factor (TF) in monocytes. In support of this hypothesis, we report here that oxLDL induced TF expression in human monocytic cells and monocytes. In addition, patients with familial hypercholesterolemia had elevated levels of plasma microparticle (MP) TF activity. Furthermore, a high-fat diet induced a time-dependent increase in plasma MP TF activity and activation of coagulation in both LDL receptor-deficient mice and African green monkeys. Genetic deficiency of TF in bone marrow cells reduced coagulation in hypercholesterolemic mice, consistent with a major role for monocyte-derived TF in the activation of coagulation. Similarly, a deficiency of either TLR4 or TLR6 reduced levels of MP TF activity. Simvastatin treatment of hypercholesterolemic mice and monkeys reduced oxLDL, monocyte TF expression, MP TF activity, activation of coagulation, and inflammation, without affecting total cholesterol levels. Our results suggest that the prothrombotic state associated with hypercholesterolemia is caused by oxLDL-mediated induction of TF expression in monocytes via engagement of a TLR4/TLR6 complex.
Owens et al. (Tue,) conducted a other in Hypercholesterolemia. Simvastatin was evaluated on oxLDL, monocyte TF expression, MP TF activity, activation of coagulation, and inflammation. Simvastatin treatment of hypercholesterolemic mice and monkeys reduced oxLDL, monocyte tissue factor expression, microparticle tissue factor activity, coagulation activation, and inflammation.